vs
徕博科（LH）与Primoris Services Corp（PRIM）财务数据对比。点击上方公司名可切换其他公司
徕博科的季度营收约是Primoris Services Corp的1.9倍（$3.5B vs $1.9B），徕博科净利率更高（4.7% vs 2.8%，领先1.9%），Primoris Services Corp同比增速更快（6.7% vs 5.6%），徕博科自由现金流更多（$490.3M vs $121.1M），过去两年Primoris Services Corp的营收复合增速更高（14.7% vs 5.2%）
徕博科（Labcorp）是全球领先的生命科学与诊断检测企业，面向医疗机构、制药企业和个人患者提供全面的临床检验服务、药物研发支持及医疗检测解决方案，依托先进科研经验与创新技术输出准确可落地的健康洞察，助力临床决策、加快新药研发，提升全球患者健康水平。
Primoris Services Corp是总部位于美国的上市专业基建与工程建设企业，核心业务覆盖天然气管道、污水管网及供水管道建设领域，2014年入选《财富》1000强榜单，在北美能源及民生基建领域拥有丰富的项目运营经验。
LH vs PRIM — 直观对比
营收规模更大
LH
是对方的1.9倍
$1.9B
营收增速更快
PRIM
高出1.1%
5.6%
净利率更高
LH
高出1.9%
2.8%
自由现金流更多
LH
多$369.2M
$121.1M
两年增速更快
PRIM
近两年复合增速
5.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.5B | $1.9B |
| 净利润 | $164.7M | $51.7M |
| 毛利率 | 28.2% | 9.4% |
| 营业利润率 | 7.6% | 4.2% |
| 净利率 | 4.7% | 2.8% |
| 营收同比 | 5.6% | 6.7% |
| 净利润同比 | 14.9% | -4.2% |
| 每股收益（稀释后） | $1.98 | $0.94 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LHPRIM
| Q4 25 | $3.5B | $1.9B | ||
| Q3 25 | $3.6B | $2.2B | ||
| Q2 25 | $3.5B | $1.9B | ||
| Q1 25 | $3.3B | $1.6B | ||
| Q4 24 | $3.3B | $1.7B | ||
| Q3 24 | $3.3B | $1.6B | ||
| Q2 24 | $3.2B | $1.6B | ||
| Q1 24 | $3.2B | $1.4B |
净利润LHPRIM
| Q4 25 | $164.7M | $51.7M | ||
| Q3 25 | $261.1M | $94.6M | ||
| Q2 25 | $237.9M | $84.3M | ||
| Q1 25 | $212.8M | $44.2M | ||
| Q4 24 | $143.4M | $54.0M | ||
| Q3 24 | $169.3M | $58.4M | ||
| Q2 24 | $205.3M | $49.5M | ||
| Q1 24 | $228.0M | $18.9M |
毛利率LHPRIM
| Q4 25 | 28.2% | 9.4% | ||
| Q3 25 | 28.8% | 10.8% | ||
| Q2 25 | 29.7% | 12.3% | ||
| Q1 25 | 28.3% | 10.4% | ||
| Q4 24 | 26.9% | 10.6% | ||
| Q3 24 | 27.6% | 12.0% | ||
| Q2 24 | 28.8% | 11.9% | ||
| Q1 24 | 28.2% | 9.4% |
营业利润率LHPRIM
| Q4 25 | 7.6% | 4.2% | ||
| Q3 25 | 11.1% | 6.3% | ||
| Q2 25 | 11.2% | 6.7% | ||
| Q1 25 | 9.7% | 4.3% | ||
| Q4 24 | 6.5% | 5.0% | ||
| Q3 24 | 7.7% | 6.0% | ||
| Q2 24 | 9.2% | 5.5% | ||
| Q1 24 | 10.1% | 3.1% |
净利率LHPRIM
| Q4 25 | 4.7% | 2.8% | ||
| Q3 25 | 7.3% | 4.3% | ||
| Q2 25 | 6.7% | 4.5% | ||
| Q1 25 | 6.4% | 2.7% | ||
| Q4 24 | 4.3% | 3.1% | ||
| Q3 24 | 5.2% | 3.5% | ||
| Q2 24 | 6.4% | 3.2% | ||
| Q1 24 | 7.2% | 1.3% |
每股收益（稀释后）LHPRIM
| Q4 25 | $1.98 | $0.94 | ||
| Q3 25 | $3.12 | $1.73 | ||
| Q2 25 | $2.84 | $1.54 | ||
| Q1 25 | $2.52 | $0.81 | ||
| Q4 24 | $1.72 | $0.98 | ||
| Q3 24 | $2.00 | $1.07 | ||
| Q2 24 | $2.43 | $0.91 | ||
| Q1 24 | $2.69 | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $532.3M | $535.5M |
| 总债务越低越好 | — | $469.9M |
| 股东权益账面价值 | $8.6B | $1.7B |
| 总资产 | $18.4B | $4.4B |
| 负债/权益比越低杠杆越低 | — | 0.28× |
8季度趋势，按日历期对齐
现金及短期投资LHPRIM
| Q4 25 | $532.3M | $535.5M | ||
| Q3 25 | $598.1M | $431.4M | ||
| Q2 25 | $647.3M | $390.3M | ||
| Q1 25 | $369.4M | $351.6M | ||
| Q4 24 | $1.5B | $455.8M | ||
| Q3 24 | $1.5B | $352.7M | ||
| Q2 24 | $265.1M | $207.4M | ||
| Q1 24 | $99.3M | $177.6M |
总债务LHPRIM
| Q4 25 | — | $469.9M | ||
| Q3 25 | — | $486.0M | ||
| Q2 25 | — | $603.1M | ||
| Q1 25 | — | $612.0M | ||
| Q4 24 | — | $734.8M | ||
| Q3 24 | — | $903.7M | ||
| Q2 24 | — | $933.0M | ||
| Q1 24 | — | $951.7M |
股东权益LHPRIM
| Q4 25 | $8.6B | $1.7B | ||
| Q3 25 | $8.7B | $1.6B | ||
| Q2 25 | $8.5B | $1.5B | ||
| Q1 25 | $8.3B | $1.4B | ||
| Q4 24 | $8.1B | $1.4B | ||
| Q3 24 | $8.2B | $1.4B | ||
| Q2 24 | $8.0B | $1.3B | ||
| Q1 24 | $8.0B | $1.2B |
总资产LHPRIM
| Q4 25 | $18.4B | $4.4B | ||
| Q3 25 | $18.3B | $4.6B | ||
| Q2 25 | $18.1B | $4.5B | ||
| Q1 25 | $17.6B | $4.2B | ||
| Q4 24 | $18.4B | $4.2B | ||
| Q3 24 | $18.6B | $4.2B | ||
| Q2 24 | $16.7B | $4.0B | ||
| Q1 24 | $16.5B | $4.0B |
负债/权益比LHPRIM
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.39× | ||
| Q1 25 | — | 0.42× | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 0.67× | ||
| Q2 24 | — | 0.72× | ||
| Q1 24 | — | 0.76× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $614.2M | $142.9M |
| 自由现金流经营现金流 - 资本支出 | $490.3M | $121.1M |
| 自由现金流率自由现金流/营收 | 13.9% | 6.5% |
| 资本支出强度资本支出/营收 | 3.5% | 1.2% |
| 现金转化率经营现金流/净利润 | 3.73× | 2.76× |
| 过去12个月自由现金流最近4个季度 | $1.2B | $340.5M |
8季度趋势，按日历期对齐
经营现金流LHPRIM
| Q4 25 | $614.2M | $142.9M | ||
| Q3 25 | $387.2M | $182.9M | ||
| Q2 25 | $620.6M | $78.5M | ||
| Q1 25 | $18.5M | $66.2M | ||
| Q4 24 | $777.2M | $298.3M | ||
| Q3 24 | $277.3M | $222.5M | ||
| Q2 24 | $561.1M | $16.1M | ||
| Q1 24 | $-29.8M | $-28.5M |
自由现金流LHPRIM
| Q4 25 | $490.3M | $121.1M | ||
| Q3 25 | $280.5M | $148.4M | ||
| Q2 25 | $542.7M | $45.3M | ||
| Q1 25 | $-107.5M | $25.6M | ||
| Q4 24 | $665.1M | $270.0M | ||
| Q3 24 | $161.5M | $158.8M | ||
| Q2 24 | $432.9M | $-8.1M | ||
| Q1 24 | $-163.6M | $-38.9M |
自由现金流率LHPRIM
| Q4 25 | 13.9% | 6.5% | ||
| Q3 25 | 7.9% | 6.8% | ||
| Q2 25 | 15.4% | 2.4% | ||
| Q1 25 | -3.2% | 1.6% | ||
| Q4 24 | 20.0% | 15.5% | ||
| Q3 24 | 4.9% | 9.6% | ||
| Q2 24 | 13.4% | -0.5% | ||
| Q1 24 | -5.2% | -2.8% |
资本支出强度LHPRIM
| Q4 25 | 3.5% | 1.2% | ||
| Q3 25 | 3.0% | 1.6% | ||
| Q2 25 | 2.2% | 1.8% | ||
| Q1 25 | 3.8% | 2.5% | ||
| Q4 24 | 3.4% | 1.6% | ||
| Q3 24 | 3.5% | 3.9% | ||
| Q2 24 | 4.0% | 1.5% | ||
| Q1 24 | 4.2% | 0.7% |
现金转化率LHPRIM
| Q4 25 | 3.73× | 2.76× | ||
| Q3 25 | 1.48× | 1.93× | ||
| Q2 25 | 2.61× | 0.93× | ||
| Q1 25 | 0.09× | 1.50× | ||
| Q4 24 | 5.42× | 5.53× | ||
| Q3 24 | 1.64× | 3.81× | ||
| Q2 24 | 2.73× | 0.32× | ||
| Q1 24 | -0.13× | -1.50× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LH
| Diagnostics | $2.7B | 78% |
| Biopharma Laboratory Services | $793.0M | 23% |
PRIM
| Energy Segment | $1.2B | 64% |
| Unit Price Contracts | $473.7M | 25% |
| Cost Reimbursable Contracts | $121.3M | 7% |
| Other | $74.9M | 4% |
